Sanofi Myeloma Drug Sarclisa Met Primary Goal in Late-Stage Trial

By Adria Calatayud

Sanofi said a late-stage clinical trial for its Sarclisa drug in combination with other drugs met its primary goal of progression-free survival in patients with newly diagnosed multiple myeloma.

The French pharmaceutical company said Thursday the results came from a planned interim analysis for efficacy in a phase 3 trial that studies the investigational use of Sarclisa in combination with standard-of-care bortezomib, lenalidomide and dexamethasone against the standard of care alone.
The safety and tolerability of Sarclisa in the trial was consistent with its established safety profile, Sanofi said.
The company said the study results will form the basis of a future regulatory submission.
“This is the second phase 3 trial investigating Sarclisa in newly diagnosed patients to show superiority versus standard of care, reinforcing our belief in Sarclisa as a best-in-class medicine,” said Dietmar Berger, Sanofi’s global head of development.
Write to Adria Calatayud at adria.calatayud@dowjones.com